Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
Infect Immun. 1996 May; 64(5): 1659–1665.
PMCID: PMC173976

A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.


The efficacy of capsular polysaccharide (CP)-specific antibodies elicited by active immunization with vaccines composed of Staphylococcus aureus types 5 and 8 CP linked to Pseudomonas aeruginosa exoprotein A or with immune immunoglobulin G (I-IgG) obtained from vaccinated plasma donors was tested in lethal and sublethal bacterial mouse challenge models. A dose of 2 x 10(5) CFU of S. aureus type 5 CP per mouse administered intraperitoneally (i.p.) with 5% hog mucin was found to cause 80 to 100% mortality in BALB/c mice within 2 to 5 days. Mice passively immunized i.p. 24 h earlier or subcutaneously 48 h earlier with 0.5 ml of I-IgG showed significantly higher average survival rates than animals receiving standard IgG or saline (P < 0.01) following the bacterial challenge. Animals actively immunized with the monovalent type 5 CP-P. aeruginosa exoprotein A conjugate showed a survival rate of 73% compared with 13% in phosphate-buffered saline-immunized animals. The prechallenge geometric mean titer of type 5 CP antibodies in animals that died was significantly (P < 0.05) lower than that of animals which survived the challenge (95.7 versus 223.6 micrograms/ml, respectively). The IgG was further evaluated in mice challenged i.p. with a sublethal dose of 5 x 10(4) CFU per mouse. Serial blood counts were performed on surviving animals at 6, 12, 24, and 48 h. Surviving animals were sacrificed at 72 h, and bacterial counts were performed on their kidneys, livers, and peritoneal lavage fluids. Animals receiving I-IgG had lower bacterial counts in blood samples and lower bacterial densities in kidneys, livers, and peritoneal lavage samples than mice immunized with standard IgG (P < 0.05). These data suggest that S. aureus type 5 CP antibodies induced by active immunization or administered by passive immunization confer protection against S. aureus infections.

Full Text

The Full Text of this article is available as a PDF (301K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Albus A, Arbeit RD, Lee JC. Virulence of Staphylococcus aureus mutants altered in type 5 capsule production. Infect Immun. 1991 Mar;59(3):1008–1014. [PMC free article] [PubMed]
  • Albus A, Fournier JM, Wolz C, Boutonnier A, Ranke M, Høiby N, Hochkeppel H, Döring G. Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis. J Clin Microbiol. 1988 Dec;26(12):2505–2509. [PMC free article] [PubMed]
  • Arbeit RD, Dunn RM. Expression of capsular polysaccharide during experimental focal infection with Staphylococcus aureus. J Infect Dis. 1987 Dec;156(6):947–952. [PubMed]
  • Arbeit RD, Karakawa WW, Vann WF, Robbins JB. Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis. 1984 Apr;2(2):85–91. [PubMed]
  • Arbeit RD, Nelles MJ. Capsular polysaccharide antigenemia in rats with experimental endocarditis due to Staphylococcus aureus. J Infect Dis. 1987 Feb;155(2):242–246. [PubMed]
  • Baddour LM, Lowrance C, Albus A, Lowrance JH, Anderson SK, Lee JC. Staphylococcus aureus microcapsule expression attenuates bacterial virulence in a rat model of experimental endocarditis. J Infect Dis. 1992 Apr;165(4):749–753. [PubMed]
  • Boutonnier A, Nato F, Bouvet A, Lebrun L, Audurier A, Mazie JC, Fournier JM. Direct testing of blood culture for detection of the serotype 5 and 8 capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol. 1989 May;27(5):989–993. [PMC free article] [PubMed]
  • Bryant RE, Sanford JP, Alcoze T. Treatment of recurrent furunculosis with staphylococcal bacteriophage-lysed vaccine. JAMA. 1965 Oct 4;194(1):11–14. [PubMed]
  • Dassy B, Stringfellow WT, Lieb M, Fournier JM. Production of type 5 capsular polysaccharide by Staphylococcus aureus grown in a semi-synthetic medium. J Gen Microbiol. 1991 May;137(5):1155–1162. [PubMed]
  • Daum RS, Fattom A, Freese S, Karakawa W. Capsular polysaccharide serotypes of coagulase-positive staphylococci associated with tenosynovitis, osteomyelitis, and other invasive infections in chickens and turkeys: evidence for new capsular types. Avian Dis. 1994 Oct-Dec;38(4):762–771. [PubMed]
  • DILLENBERG H. Experiences with a polyvalent staphylococcal vaccine with alpha-toxoid. Can J Public Health. 1962 Jun;53:248–253. [PubMed]
  • Ekstedt RD. Immune response to surface antigens of Staphylococcus aureus and their role in resistance to staphylococcal disease. Ann N Y Acad Sci. 1974 Jul 31;236(0):203–220. [PubMed]
  • Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, Li X, Shiloach J, Bryla DA, Robbins JB. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun. 1993 Mar;61(3):1023–1032. [PMC free article] [PubMed]
  • Fattom A, Schneerson R, Szu SC, Vann WF, Shiloach J, Karakawa WW, Robbins JB. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun. 1990 Jul;58(7):2367–2374. [PMC free article] [PubMed]
  • Fattom A, Shiloach J, Bryla D, Fitzgerald D, Pastan I, Karakawa WW, Robbins JB, Schneerson R. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate. Infect Immun. 1992 Feb;60(2):584–589. [PMC free article] [PubMed]
  • FISHER S. Observations on an antistaphylococcal mouse protective antibody in human sera. Aust J Exp Biol Med Sci. 1961 Oct;39:413–421. [PubMed]
  • Foster TJ. Potential for vaccination against infections caused by Staphylococcus aureus. Vaccine. 1991 Apr;9(4):221–227. [PubMed]
  • Fournier JM, Hannon K, Moreau M, Karakawa WW, Vann WF. Isolation of type 5 capsular polysaccharide from Staphylococcus aureus. Ann Inst Pasteur Microbiol. 1987 Sep-Oct;138(5):561–567. [PubMed]
  • Fournier JM, Vann WF, Karakawa WW. Purification and characterization of Staphylococcus aureus type 8 capsular polysaccharide. Infect Immun. 1984 Jul;45(1):87–93. [PMC free article] [PubMed]
  • Greenberg DP, Ward JI, Bayer AS. Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits. Infect Immun. 1987 Dec;55(12):3030–3034. [PMC free article] [PubMed]
  • GREENBERG L, COOPER MY. Polyvalent somatic antigen for the prevention of staphylococcal infection. Can Med Assoc J. 1960 Jul 23;83:143–147. [PMC free article] [PubMed]
  • GREENBERG L, LE RICHE WH. Staphylococcal enzyme lysed soluble vaccine. Can J Public Health. 1961 Nov;52:479–485. [PubMed]
  • Heidelberger M, Macpherson CF. QUANTITATIVE MICRO-ESTIMATION OF ANTIBODIES IN THE SERA OF MAN AND OTHER ANIMALS. Science. 1943 Apr 30;97(2522):405–406. [PubMed]
  • Hochkeppel HK, Braun DG, Vischer W, Imm A, Sutter S, Staeubli U, Guggenheim R, Kaplan EL, Boutonnier A, Fournier JM. Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8. J Clin Microbiol. 1987 Mar;25(3):526–530. [PMC free article] [PubMed]
  • Karakawa WW, Fournier JM, Vann WF, Arbeit R, Schneerson RS, Robbins JB. Method for the serological typing of the capsular polysaccharides of Staphylococcus aureus. J Clin Microbiol. 1985 Sep;22(3):445–447. [PMC free article] [PubMed]
  • Karakawa WW, Sutton A, Schneerson R, Karpas A, Vann WF. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun. 1988 May;56(5):1090–1095. [PMC free article] [PubMed]
  • KOENIG MG. Factors relating to the virulence of staphylococci. I. Comparative studies on two colonial variants. Yale J Biol Med. 1962 Jun;34:537–559. [PMC free article] [PubMed]
  • Koenig MG, Melly MA. The importance of surface antigens in staphylococcal virulence. Ann N Y Acad Sci. 1965 Jul 23;128(1):231–250. [PubMed]
  • Lee JC, Betley MJ, Hopkins CA, Perez NE, Pier GB. Virulence studies, in mice, of transposon-induced mutants of Staphylococcus aureus differing in capsule size. J Infect Dis. 1987 Nov;156(5):741–750. [PubMed]
  • Lee JC, Perez NE, Hopkins CA, Pier GB. Purified capsular polysaccharide-induced immunity to Staphylococcus aureus infection. J Infect Dis. 1988 Apr;157(4):723–730. [PubMed]
  • Lee JC, Takeda S, Livolsi PJ, Paoletti LC. Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus. Infect Immun. 1993 May;61(5):1853–1858. [PMC free article] [PubMed]
  • Melly MA, Duke LJ, Liau DF, Hash JH. Biological properties of the encapsulated Staphylococcus aureus M. Infect Immun. 1974 Aug;10(2):389–397. [PMC free article] [PubMed]
  • Melly MA, McGee ZA, Horn RG, Morris F, Glick AD. An electron microscopic India ink technique for demonstrating capsules on microorganisms: studies with Streptococcus pneumoniae, Staphylococcus aureus, and Neisseria gonorrhoeae. J Infect Dis. 1979 Oct;140(4):605–609. [PubMed]
  • Moreau M, Richards JC, Fournier JM, Byrd RA, Karakawa WW, Vann WF. Structure of the type 5 capsular polysaccharide of Staphylococcus aureus. Carbohydr Res. 1990 Jul 1;201(2):285–297. [PubMed]
  • Nemeth J, Lee JC. Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis. Infect Immun. 1995 Feb;63(2):375–380. [PMC free article] [PubMed]
  • Peterson PK, Wilkinson BJ, Kim Y, Schmeling D, Quie PG. Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes. Infect Immun. 1978 Mar;19(3):943–949. [PMC free article] [PubMed]
  • Poutrel B, Boutonnier A, Sutra L, Fournier JM. Prevalence of capsular polysaccharide types 5 and 8 among Staphylococcus aureus isolates from cow, goat, and ewe milk. J Clin Microbiol. 1988 Jan;26(1):38–40. [PMC free article] [PubMed]
  • Poutrel B, Gilbert FB, Lebrun M. Effects of culture conditions on production of type 5 capsular polysaccharide by human and bovine Staphylococcus aureus strains. Clin Diagn Lab Immunol. 1995 Mar;2(2):166–171. [PMC free article] [PubMed]
  • Poutrel B, Sutra L. Type 5 and 8 capsular polysaccharides are expressed by Staphylococcus aureus isolates from rabbits, poultry, pigs, and horses. J Clin Microbiol. 1993 Feb;31(2):467–469. [PMC free article] [PubMed]
  • Quie PG. Bactericidal function of human polymorphonuclear leukocytes. E. Mead Johnson Award Address. Pediatrics. 1972 Aug;50(2):264–270. [PubMed]
  • Robbins JB, Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis. 1990 May;161(5):821–832. [PubMed]
  • Rogers DE, Melly MA. Speculations on the immunology of staphylococcal infections. Ann N Y Acad Sci. 1965 Jul 23;128(1):274–284. [PubMed]
  • Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980 Aug 1;152(2):361–376. [PMC free article] [PubMed]
  • Stringfellow WT, Dassy B, Lieb M, Fournier JM. Staphylococcus aureus growth and type 5 capsular polysaccharide production in synthetic media. Appl Environ Microbiol. 1991 Feb;57(2):618–621. [PMC free article] [PubMed]
  • Sutra L, Mendolia C, Rainard P, Poutrel B. Encapsulation of Staphylococcus aureus isolates from mastitic milk: relationship between capsular polysaccharide types 5 and 8 and colony morphology in serum-soft agar, clumping factor, teichoic acid, and protein A. J Clin Microbiol. 1990 Mar;28(3):447–451. [PMC free article] [PubMed]
  • Sutra L, Rainard P, Poutrel B. Phagocytosis of mastitis isolates of Staphylococcus aureus and expression of type 5 capsular polysaccharide are influenced by growth in the presence of milk. J Clin Microbiol. 1990 Oct;28(10):2253–2258. [PMC free article] [PubMed]
  • Sutton A, Vann WF, Karpas AB, Stein KE, Schneerson R. An avidin-biotin based ELISA for quantitation of antibody to bacterial polysaccharides. J Immunol Methods. 1985 Oct 10;82(2):215–224. [PubMed]
  • Xu S, Arbeit RD, Lee JC. Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun. 1992 Apr;60(4):1358–1362. [PMC free article] [PubMed]
  • Yoshida K, Ichiman Y, Narikawa S, Evans WB. Staphylococcal capsular vaccine for preventing mastitis in two herds in Georgia. J Dairy Sci. 1984 Mar;67(3):620–627. [PubMed]
  • Yoshida K, Ichiman Y, Narikawa S, Takahashi M, Kono E, San Clemente CL. Passive protection by human serum in mice infected with encapsulated Staphylococcus aureus. J Med Microbiol. 1979 Aug;12(3):277–282. [PubMed]
  • Zollinger WD, Boslego JW. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J Immunol Methods. 1981;46(2):129–140. [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...